Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
Launched by ABBVIE · Mar 27, 2019
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants who have been prescribed Humira by their treating physician as per routine clinical practice for the treatment of HS.
- Exclusion Criteria:
- • Participants previously treated with Humira.
- • Participants who do not provide consent.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Anjo Shi, Aichi, Japan
Ichinomiya Shi, Aichi, Japan
Nagakute Shi, Aichi, Japan
Nagoya Shi, Aichi, Japan
Nagoyashi, Aichi, Japan
Kisarazu Shi, Chiba, Japan
Toon Shi, Ehime, Japan
Fukuoka Shi, Fukuoka, Japan
Kitakyushu Shi, Fukuoka, Japan
Hatsukaichi Shi, Hiroshima, Japan
Sapporo Shi, Hokkaido, Japan
Kobe Shi, Hyogo, Japan
Kobe Shi, Hyogo, Japan
Takarazuka Shi, Hyogo, Japan
Mito Shi, Ibaraki, Japan
Yokohama Shi, Kanagawa, Japan
Yokosuka Shi, Kanagawa, Japan
Nankoku Shi, Kochi, Japan
Kyoto Shi, Kyoto, Japan
Yokkaichi Shi, Mie, Japan
Sendai Shi, Miyagi, Japan
Sendai Shi, Miyagi, Japan
Ikoma Shi, Nara, Japan
Okayama Shi, Okayama, Japan
Nakagami Gun, Okinawa, Japan
Kishiwada Shi, Osaka, Japan
Osakasayama Shi, Osaka, Japan
Suita Shi, Osaka, Japan
Takatsuki Shi, Osaka, Japan
Iruma Gun, Saitama, Japan
Kawagoe Shi, Saitama, Japan
Hamamatsu Shi, Shizuoka, Japan
Shizuoka Shi, Shizuoka, Japan
Minato Ku, Tokyo, Japan
Shinjuku Ku, Tokyo, Japan
Toyama Shi, Toyama, Japan
Hokkaido, , Japan
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials